A new clinical trial suggests that giving immunotherapy before surgery may dramatically improve outcomes for certain colorectal cancer patients. In the NEOPRISM-CRC study, patients treated with a short course of immunotherapy instead of chemotherapy after surgery have remained cancer-free for nearly three years. The trial, led by researchers at UCL and UCLH, found that just nine weeks of treatment with pembrolizumab before surgery led to strong and lasting responses in patients with stage two or three colorectal cancer. No Cancer Recurrence After Nearly Three Years Early results showed that 59% of patients had no detectable cancer after completing immunotherapy and undergoing surgery. Now, after 33 months of follow-up, none of the patients have experienced a relapse. This includes both patients whose tumors completely disappeared and those who still had small traces of cancer after treatment. In all cases, the remaining cancer did not grow or spread over time.…